<?xml version="1.0" encoding="UTF-8" ?>

       <rss version="2.0">

       <channel>

          <title>NewsVoir</title>

          <link>http://newsvoir.com</link><item>		

		 <title><![CDATA[StayVista Offers Complimentary Stays to India's Olympians, Rallying them to #TakeABreak After a Sensational Performance]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=29141</link>

		 <description><![CDATA[
	​India's largest villa rental brand is ready to host our Paris 2024 Olympics heroes for free vacations worth upto Rs. 50 lakhs. Once the games come to a close, StayVista wants to give them something they well and truly deserve after an exhilarating display: A Vacation. The brand is inviting our....]]></description>

		 <pubDate><![CDATA[Sat, 10 Aug 2024 05:33:24]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Budget Expectation from Mr Pawan Chaudhary, CMD, Venus Remedies]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=3452</link>

		 <description><![CDATA[
	Quote of Mr Pawan Chaudhary, Chairman and Managing Director, Venus Remedies on his expectations from the 2015-16 Union Budget:


	 


	The Union Finance Minister should take his government's "Make in India" campaign to the next level by taking steps to boost indigenous research. He should g....]]></description>

		 <pubDate><![CDATA[Tue, 24 Feb 2015 18:18:34]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Venus Remedies Bags Indian Patent for Vancoplus]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=3259</link>

		 <description><![CDATA[
	
		
			The novel antibiotic adjuvant entity is highly effective against drug-resistant infections, different resistance mechanisms which no other existing therapeutic options available in the market are able to tackle
	
	
		
			Vancoplus projected to cater to a market of Rs 214 crore in Ind....]]></description>

		 <pubDate><![CDATA[Mon, 09 Feb 2015 15:51:07]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Venus Strengthens Portfolio in Swiss Market with Marketing Authorisation for Meropenem]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=2247</link>

		 <description><![CDATA[
	
		
			Gets approval from Swiss drug authority Swissmedic through its German subsidiary Venus Pharma GmbH for meropenem 500 mg, 1 g injections
	
	
		
			With plans to launch the product early next year through its partner Swiss Pharma GmbH Zurich, Venus eyes 10% share in Switzerland's merop....]]></description>

		 <pubDate><![CDATA[Tue, 11 Nov 2014 18:49:17]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Venus Forays Into Singapore's Topical Pain Management Market with Marketing Approval, Patent for Trois]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=1763</link>

		 <description><![CDATA[
	
		
			Company holding talks with various pharmaceutical firms for tie-ups
	
	
		
			Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffer....]]></description>

		 <pubDate><![CDATA[Thu, 25 Sep 2014 13:46:34]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Venus Ties Up with Mylan for Marketing Meropenem in Three European Countries]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=1582</link>

		 <description><![CDATA[
	
		
			The distribution-cum-outlicensing agreement between Venus Pharma GmbH, Germany and Mylan will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for five years
	
	
		
			While the drug will be manufactured at Venus Remedies' Baddi facility, batch release and log....]]></description>

		 <pubDate><![CDATA[Mon, 08 Sep 2014 11:38:15]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Venus Remedies Ties up With Teva for Anti-Cancer Drug to Enter Canadian Market for First Time]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=1502</link>

		 <description><![CDATA[
	
		Venus will initially manufacture the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations, after which the company will use its manufacturing capabilities to support Teva in enhancing business from this drug in Canada


	 

	
		While Teva wi....]]></description>

		 <pubDate><![CDATA[Tue, 26 Aug 2014 17:41:06]]></pubDate>

		 </item><item>		

		 <title><![CDATA[Venus Bags its First Swiss Marketing Authorisation for Gemcitabine]]></title>

		 <link>http://newsvoir.com/index.php?option=com_content&amp;view=release&amp;rid=1459</link>

		 <description><![CDATA[
	
		
			Being among the first few pharma firms to receive marketing authorisation for Gemcitabine, an oncology drug, and the first Indian company to get marketing approval for this product from Switzerland, Venus Remedies enjoys a competitive edge over other players and is all set to capture a s....]]></description>

		 <pubDate><![CDATA[Wed, 20 Aug 2014 16:43:20]]></pubDate>

		 </item>

</channel>

</rss>